Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101

Galimedix Therapeutics, Inc., a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today…

Continue ReadingGalimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101

Siemens Healthineers and Novo join forces to advance care for people living with MASLD and MASH

Siemens Healthineers and Novo have announced a collaboration focused on advancing care for people living with metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH).

Continue ReadingSiemens Healthineers and Novo join forces to advance care for people living with MASLD and MASH